Response to: Correspondence on “Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab” by Gao et al 19 de June de 2025 by Graser, C., McDonald, T. O., Catalano, P. J., Sonpavde, G., Michor, F.
Graser, C., McDonald, T. O., Catalano, P. J., Sonpavde, G., Michor, F. 